This Phase I , open-label , three-period , cross-over pharmacokinetic study enrolled healthy males and females who , following consent and screening procedures , were randomized to receive SJW on days @-@ , SJW plus boceprevir ( SJW on days @-@ and together on days @-@ ) and boceprevir on days @-@ , separated by @ day washout periods , or the same treatment in the opposite order .